---
title: "禮來公司（LLY）獲得了花旗銀行的買入評級"
description: "Meacham 涉及醫療保健行業，關注的股票包括禮來公司、安進和 Vertex Pharmaceuticals。根據 TipRanks 的數據，Meacham 推薦股票的平均回報率為 4.2%，成功率為 55.14%。除了花旗集團，禮來公司還在 10 月 10 日的報告中獲得了富國銀行的 Mohit Bansal 的買入評級。然而，滙豐銀行在 10 月 1 日對禮來公司（紐約證券交易所代碼：LLY"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/260882061.md"
published_at: "2025-10-13T10:55:53.000Z"
---

# 禮來公司（LLY）獲得了花旗銀行的買入評級

> Meacham 涉及醫療保健行業，關注的股票包括禮來公司、安進和 Vertex Pharmaceuticals。根據 TipRanks 的數據，Meacham 推薦股票的平均回報率為 4.2%，成功率為 55.14%。除了花旗集團，禮來公司還在 10 月 10 日的報告中獲得了富國銀行的 Mohit Bansal 的買入評級。然而，滙豐銀行在 10 月 1 日對禮來公司（紐約證券交易所代碼：LLY）維持了持有評級

Meacham 關注醫療保健行業，重點分析如禮來公司、安進和 Vertex Pharmaceuticals 等股票。根據 TipRanks 的數據，Meacham 推薦股票的平均回報率為 4.2%，成功率為 55.14%。

除了花旗，禮來公司還在 10 月 10 日的報告中獲得了富國銀行的 Mohit Bansal 的買入評級。然而，在 10 月 1 日，滙豐維持了對禮來公司（紐約證券交易所代碼：LLY）的持有評級。

### Related Stocks

- [LLY.US - 禮來](https://longbridge.com/zh-HK/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/zh-HK/news/275971336.md) |
| Jim Cramer discusses Eli Lilly (LLY) & weight loss drugs | Jim Cramer recently discussed Eli Lilly and Company (NYSE:LLY), which has seen its shares rise by 23.5% over the past ye | [Link](https://longbridge.com/zh-HK/news/276258256.md) |
| Eli Lilly and Company $LLY Shares Bought by Balentine LLC | Balentine LLC increased its stake in Eli Lilly and Company (NYSE: LLY) by 150.1% in Q3, owning 4,042 shares valued at $3 | [Link](https://longbridge.com/zh-HK/news/276105002.md) |
| Eli Lilly Stock (LLY) Rises on Plan to Invest $1 Billion in India | Eli Lilly's stock (LLY) rose approximately 1% following the announcement of a $1 billion investment in India to enhance  | [Link](https://longbridge.com/zh-HK/news/276152620.md) |
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/zh-HK/news/276070062.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。